Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RaDD: Radiotherapy and Durvalumab in Relapsed/Refractory DLBCL and FL
NCT03610061Phase 1Completed
- Sponsor
- Austin Health
- Start
- Nov 2018
- Primary completion
- Apr 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Austin Health. Primary endpoints: Treatment-related adverse events at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started Nov 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03610061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610061.